論文・総説 - 田中 真二

分割表示  368 件中 161 - 180 件目  /  全件表示 >>
  1. Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N.. Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology. 2014.01; 86 (1): 53-62. ( PubMed, DOI )

  2. Kano Y, Konno M, Kawamoto K, Tamari K, Hayashi K, Fukusumi T, Satoh T, Tanaka S, Ogawa K, Mori M, Doki Y, Ishii H. Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. Oncology Reports. 2014; 86 (1): 53-62.

  3. Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma; clinical and biological significance. Hepatology. 2013; 57 (4): 1436-1447. ( PubMed, DOI )

  4. Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. . Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. Visualization of stem cell features in human hepatocellular carcinoma enlightened in vivo significance of tumor-host interaction and clinical implication. Hepatology, 58:218-228, 2013 Hepatology. 2013; 58 218 -228.

  5. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology, 143:234-245, 2012 Gastroenterology, 143:234-245, 2012 . 2012;

  6. Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. . Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor-suppressor in hepatocellular carcinoma. Clinical Cancer Research, 18:3541-3551, 2012 Clinical Cancer Research, 18:3541-3551, 2012. 2012;

  7. Tanaka S, Arii S.. Tanaka S, Arii S. Molecular targeted therapy in hepatocellular carcinoma. Seminars in Oncology, 39:486-92, 2012 Seminars in Oncology, 39:486-92, 2012. 2012;

  8. Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. . Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. Oxidative stress pathways in non-cancerous human liver tissue to predict hepatocellular carcinoma recurrence; a prospective multi-center study. Hepatology, 54:1273-1281, 2011 Hepatology, 54:1273-1281, 2011. 2011;

  9. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Gene expression signature of the gross morphology in hepatocellular carcinoma. Annals of Surgery, 253:94-100, 2011 Annals of Surgery, 253:94-100, 2011. 2011;

  10. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. Journal of Hepatology, 52:63-71, 2010 Journal of Hepatology, 52:63-71, 2010. 2010;

  11. Tanaka S, Arii S.. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science, 100:1-8, 2009 Cancer Science, 100:1-8, 2009. 2009;

  12. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H.. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Aurora kinase B is a predictive factor for aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. British Journal of Surgery, 95:611-619, 2008 British Journal of Surgery, 95:611-619, 2008. 2008;

  13. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. . Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. Journal of the American College of Surgeons, 204:1-6, 2007 Journal of the American College of Surgeons, 204:1-6, 2007. 2007;

  14. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. Journal of the National Cancer Institute, 98:491-498, 2006 Journal of the National Cancer Institute, 98:491-498, 2006. 2006;

  15. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. Journal of Hepatology, 43:854-62, 2005 Journal of Hepatology, 43:854-62, 2005. 2005;

  16. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. The newly established human hepatocyte cell line: application for the bioartificial liver. Journal of Hepatology, 42:557-64, 2005 Journal of Hepatology, 42:557-64, 2005. 2005;

  17. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. . Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. Journal of Clinical Oncology, 22:4165-73, 2004 Journal of Clinical Oncology, 22:4165-73, 2004. 2004;

  18. Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. . Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 112:184-9, 2004 International Journal of Cancer, 112:184-9, 2004. 2004;

  19. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. . Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 127(4):1110-22, 2004 Gastroenterology, 127(4):1110-22, 2004. 2004;

  20. Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. . Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. Human WISP1v, a member of CCN family, is associated with invasive cholangiocarcinoma. Hepatology, 37:1122-9, 2003 Hepatology, 37:1122-9, 2003. 2003;

このページの先頭へ▲